Commonwealth Equity Services Inc Acquires 1,294 Shares of Novartis AG (NVS)
Commonwealth Equity Services Inc increased its holdings in shares of Novartis AG (NYSE:NVS) by 0.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 244,841 shares of the company’s stock after acquiring an additional 1,294 shares during the period. Commonwealth Equity Services Inc’s holdings in Novartis AG were worth $21,019,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of NVS. City Holding Co. boosted its position in shares of Novartis AG by 4.6% during the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after acquiring an additional 54 shares in the last quarter. WFG Advisors LP boosted its position in Novartis AG by 38.1% in the second quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after buying an additional 337 shares in the last quarter. Archford Capital Strategies LLC boosted its position in Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after buying an additional 621 shares in the last quarter. Kernodle & Katon Asset Management Group LLC boosted its position in Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares in the last quarter. Finally, Cable Hill Partners LLC boosted its position in Novartis AG by 588.8% in the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after buying an additional 1,107 shares in the last quarter. Institutional investors and hedge funds own 11.00% of the company’s stock.
A number of research firms have commented on NVS. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a research report on Tuesday, October 31st. Zacks Investment Research upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Barclays PLC lowered shares of Novartis AG from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Finally, Leerink Swann boosted their price target on shares of Novartis AG from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $85.32.
Shares of Novartis AG (NVS) traded down $0.43 during mid-day trading on Thursday, hitting $82.60. 838,900 shares of the stock were exchanged, compared to its average volume of 2,331,740. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The firm has a market capitalization of $218,450.00, a price-to-earnings ratio of 17.48, a price-to-earnings-growth ratio of 2.65 and a beta of 0.72. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81.
Novartis AG (NYSE:NVS) last announced its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.04. Novartis AG had a net margin of 13.73% and a return on equity of 15.77%. The company had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. During the same period in the prior year, the business earned $1.23 earnings per share. Novartis AG’s quarterly revenue was up 2.4% on a year-over-year basis. equities research analysts anticipate that Novartis AG will post 4.75 earnings per share for the current year.
Novartis AG Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.